Related Experiment Videos
High-dose therapy with stem-cell transplantation in the malignant lymphomas
1Division of Hematology/Oncology, Northwestern University, Medical School, Chicago, Illinois, USA.
Oncology (Williston Park, N.Y.)
|January 13, 2000
Summary
High-dose therapy with hematopoietic progenitor-cell transplantation is crucial for treating lymphomas. Further research is needed to optimize its use, especially for allogeneic transplantation in lymphoid malignancies.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- High-dose therapy with hematopoietic progenitor-cell transplantation is a cornerstone in managing Hodgkin's disease and non-Hodgkin's lymphomas.
- It is primarily utilized as a salvage strategy for patients with relapsed or refractory disease after initial chemotherapy.
Purpose of the Study:
- To review the current role and unresolved questions surrounding high-dose therapy and transplantation in lymphoid malignancies.
- To highlight the need for further research, particularly Phase III studies, to clarify optimal treatment strategies.
Main Methods:
- Review of existing literature and clinical trial data on hematopoietic progenitor-cell transplantation for lymphomas.
- Discussion of current practices and future research directions in the field.
Main Results:
- Autologous transplantation is currently the predominant method for most patient groups.
- Emerging reduced-toxicity allogeneic transplantation techniques may expand its application in lymphoid diseases.
Conclusions:
- Significant questions remain regarding the precise application of high-dose therapy and transplantation, including the role of allogeneic transplantation and optimal timing.
- Phase III studies are essential to address these uncertainties and guide future clinical practice.
- Advancements in allogeneic transplantation may increase its utilization for lymphoid malignancies.